Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sustained response to interferon-alpha plus ribavirin therapy for chronic hepatitis C is closely associated with increased dynamism of intrahepatic natural killer and natural killer T cells.
Yamagiwa S, Matsuda Y, Ichida T, Honda Y, Takamura M, Sugahara S, Ishikawa T, Ohkoshi S, Sato Y, Aoyagi Y. Yamagiwa S, et al. Among authors: ohkoshi s. Hepatol Res. 2008 Jul;38(7):664-72. doi: 10.1111/j.1872-034X.2008.00317.x. Epub 2008 Mar 4. Hepatol Res. 2008. PMID: 18328072
Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients.
Takimoto M, Ohkoshi S, Ichida T, Takeda Y, Nomoto M, Asakura H, Naito A, Mori S, Hata K, Igarashi K, Hara H, Ohta H, Soga K, Watanabe T, Kamimura T. Takimoto M, et al. Among authors: ohkoshi s. Dig Dis Sci. 2002 Jan;47(1):170-6. doi: 10.1023/a:1013244326874. Dig Dis Sci. 2002. PMID: 11837720
Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis.
Suzuki K, Ohkoshi S, Yano M, Ichida T, Takimoto M, Naitoh A, Mori S, Hata K, Igarashi K, Hara H, Ohta H, Soga K, Watanabe T, Kamimura T, Aoyagi Y. Suzuki K, et al. Among authors: ohkoshi s. Liver Int. 2003 Jun;23(3):143-7. doi: 10.1034/j.1600-0676.2003.00822.x. Liver Int. 2003. PMID: 12955876
[Detection of HDV-RNA].
Suda T, Ohkoshi S, Aoyagi Y. Suda T, et al. Among authors: ohkoshi s. Nihon Rinsho. 2004 Aug;62 Suppl 8:416-9. Nihon Rinsho. 2004. PMID: 15453358 Review. Japanese. No abstract available.
Common clinicopathological features of the patients with chronic hepatitis B virus infection who developed hepatocellular carcinoma after seroconversion to anti-HBs--a consideration of the pathogenesis of HBV-induced hepatocellular carcinoma and a strategy to inhibit it.
Tsuboi Y, Ohkoshi S, Yano M, Suzuki K, Tsubata SS, Ishihara K, Ichida T, Sugitani S, Shibazaki K, Aoyagi Y. Tsuboi Y, et al. Among authors: ohkoshi s. Hepatogastroenterology. 2006 Jan-Feb;53(67):110-4. Hepatogastroenterology. 2006. PMID: 16506387
Absence of pretreatment markers that predict the emergence of YMDD mutants during lamivudine treatment--the results of a prospective multi-center study.
Yano M, Ohkoshi S, Suzuki K, Ito S, Wakabayashi H, Sugiyama M, Watanabe T, Maeda H, Hatakeyama SA, Hatano T, Kobayashi Y, Takei S, Kohjiro H, Tsuboi Y, Takahashi T, Ishikawa T, Kamimura T, Ichida T, Aoyagi Y. Yano M, et al. Among authors: ohkoshi s. Hepatogastroenterology. 2006 Jan-Feb;53(67):124-7. Hepatogastroenterology. 2006. PMID: 16506390
251 results